Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135643 | 1.00 | MEN1 (0.45) | MEN1KMT2AHPGDAKR1B1NPC1 | |
| SCHEMBL212272 | 0.82 | AKR1B1 (0.52) | MEN1KMT2AAKR1B1NPC1RAB9A | |
| SCHEMBL22038599 | 0.82 | AKT1 (0.45) | MEN1KMT2ATSHR | |
| SCHEMBL17986810 | 0.82 | AKT1 (0.45) | MEN1KMT2ATSHR | |
| SCHEMBL1948973 | 0.82 | AKT1 (0.45) | MEN1KMT2ATSHR | |
| SCHEMBL5512649 | 0.81 | OPRK1 (0.48) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL186172 | 0.80 | MEP1B (0.50) | MEN1KMT2AAKR1B1NPC1RAB9A | |
| SCHEMBL6994848 | 0.79 | POLB (0.49) | MEN1KMT2ANPC1RAB9ACA12 | |
| Ammonia Solution, Strong SCHEMBL27504556 | 0.79 | MEP1B (0.49) | MEN1KMT2AAKR1B1NPC1RAB9A | |
| SCHEMBL24325759 | 0.78 | KMT2A (0.43) | MEN1KMT2AHPGDNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321271-B1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20240140967-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF | LEO PHARMA A/S (DK) | 2024-05-02 | — | — | US | disclosed |
| US-11673900-B2 | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof | JAPAN TOBACCO INC. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAPAN TOBACCO INC. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-11312728-B2 | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof | JAPAN TOBACCO INC. (JP) | 2022-04-26 | — | — | US | disclosed |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAPAN TOBACCO INC. (JP) | 2020-11-03 | — | — | US | disclosed |
| US-20200216470-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF | JAPAN TOBACCO INC. (JP) | 2020-07-09 | — | — | US | disclosed |
| US-20200165269-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF | SHIONOGI & CO., LTD. (JP) | 2020-05-28 | — | — | US | disclosed |
| EP-3560932-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AND SYNTHETIC INTERMEDIATE OF SAME | Japan Tobacco, Inc. (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3559003-A1 | CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560931-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE, AND COCRYSTAL OF SAID DERIVATIVE | Japan Tobacco, Inc. (JP) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018117153-A1 | CRYSTALLINE FORMS OF A JANUS KINASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2018-06-28 | — | — | WO | disclosed |
| EP-3321271-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Japan Tobacco, Inc. (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312728-B2 | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and co-crystals thereof | JAK1, JAK3, JAK2 | MEN1 4139/4885KMT2A 1509/4885HPGD 2175/4885 |
| US-11673900-B2 | Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof | JAK1, JAK3, JAK2 | MEN1 3410/4885KMT2A 1066/4885HPGD 1663/4885 |
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAK1, JAK3, JAK2 | MEN1 2347/4885KMT2A 1033/4885HPGD 4041/4885 |
| US-20200216470-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF | JAK1, JAK3, JAK2 | MEN1 3410/4885KMT2A 1066/4885HPGD 1663/4885 |
| US-20240140967-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF | JAK1, JAK3, JAK2 | MEN1 3410/4885KMT2A 1066/4885HPGD 1663/4885 |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAK1, JAK3, JAK2 | MEN1 4130/4885KMT2A 1361/4885HPGD 957/4885 |
| US-20200165269-A1 | PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND CO-CRYSTALS THEREOF | JAK1, JAK3, JAK2 | MEN1 4139/4885KMT2A 1509/4885HPGD 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.